Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
Summary
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
Study Design
Conditions
Bipolar I Disorder
Intervention
Iloperidone
Location
Vanda Investigational Site
Marlton
New Jersey
United States
08009
Status
Recruiting
Source
Vanda Pharmaceuticals
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT04127058
- ClinicalTrials.gov processed this data on October 18, 2019
Published on BioPortfolio: 2019-10-21T12:45:36-0400
Clinical Trials
Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a three-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare two depot dosage forms, and perform dose ranging of one chosen form...
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
The main objective of this study is to assess the effectiveness and safety of lamotrigine in the treatment of youth with bipolar and bipolar spectrum disorder. This is an exploratory, 12-w...
Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Di...
The purpose of this study is to look at certain structural changes in the brain in people with bipolar disorder or those with a history of Bipolar disorder. Also collecting a blood sample...
PubMed Articles
Metacognition is an important factor in the development and persistence of bipolar disorder. One of the most striking examples of impairment in metacognitive functioning in bipolar disorder is the lac...
To clarify the clinical features preceding the onset of Bipolar disorder (BD) has become a public health priority for the prevention of high morbidity and mortality. BD remains frequently under- or mi...
Lithium prophylaxis in early-onset Bipolar disorder: a descriptive study.
Subjects fulfilling DSM 5 criteria of Bipolar I disorder with onset before 18 years on Lithium prophylaxis were included. A total of 575 subjects with Bipolar Disorder were screened, 141 had early-ons...
Bipolar disorder (BPD) is a neuropsychiatric disorder with a complex pattern of inheritance. Although many genetic studies have been conducted on BPD, its genetic correlates remain uncertain. This stu...
The purpose of this article is to provide psychiatrists and other health care professionals who treat patients with major depressive disorder and bipolar disorder a set of best practices, tools, and o...
Medical and Biotech [MESH] Definitions
Bipolar Disorder
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
Quetiapine Fumarate
A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.
Lithium
An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight 6.94. Salts of lithium are used in treating BIPOLAR DISORDER.
Retinal Bipolar Cells
INTERNEURONS of the vertebrate RETINA containing two processes. They receive inputs from the RETINAL PHOTORECEPTOR CELLS and send outputs to the RETINAL GANGLION CELLS. The bipolar cells also make lateral connections in the retina with the RETINAL HORIZONTAL CELLS and with the AMACRINE CELLS.
Lurasidone Hydrochloride
A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER.
More From BioPortfolio on "Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia"
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn